PRB2

Across TCGA pan-cancer cohorts, PRB2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PRB2 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher PRB2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRB2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

ACC, THCA, and BRCA are the cancer types where PRB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.667	<.001	45	view →
THCA	DFS	Median	All	0.081	0.841	<.001	6	view →
BRCA	DFS	Median	III,IV	0.116	0.495	.025	6	view →
LIHC	OS	Median	All	0.164	0.704	.025	6	view →
LUAD	OS	Median	All	0.545	0.788	.012	4	view →
UCEC	DFS	Median	All	1.000	0.630	.032	4	view →
SKCM	DFS	Median	II,III,IV	0.801	0.661	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PRB2–ACC (DFS)

Open the ACC breakdown →